- Regioselective addition of mesitol to a 2,4-dichloropyridine
-
The regioseleethity of the addition of 2,4,6-trimethylphenol to 2,4-dichloro-3,6-dimethylpyridine can be controlled by the proper choice of catalyst and solvent. The use of catalytic eopper(I) salts and pyridine as solvent results in exclusive addition at
- Ruggeri, Sally Gut,Vanderplas, Brian C.,Anderson, Bruce G.,Breitenbach, Ralph,Urban, Frank J.,Stewart III, A. Morgan,Young, Gregory R.
-
p. 411 - 413
(2013/01/03)
-
- Corticotropin releasing factor antagonists
-
Corticotropin-releasing factor (CRF) antagonists having the formulae wherein the dashed lines, A, B, Y, Z, G, R3, R4, R5, R6, R16 and R17 are as defined in the application, and processes fo
- -
-
-
- Method of treating heart failure
-
This invention relates to method for treating a mammal which presents with heart failure comprising administering to a mammal a therapeutically effective amount of wherein 4-(1-ethyl-propoxy)-3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine and (3,6-dime
- -
-
-
- Use of 3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-pyridines for treating heart failure
-
This invention relates to treatments for a mammal which presents with heart failure comprising administering to a mammal a therapeutically effective amount of wherein 4-(1-ethyl-propoxy)-3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridine and (3,6-dimethyl-
- -
-
-
- CORTICOTROPIN RELEASING FACTOR ANTAGONISTS
-
Corticotropin-releasing factor (CRF) antagonists having formulae (I), (II) or (III) wherein the dashed lines, A, B, Y, Z, G, R. sub.3, R. sub.4, R. sub.5, R 6, R 16 and R 17 are as defined in the description, and processes for preparing them. These compou
- -
-
-